Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Opinion

Sort by: Newest first Oldest first A-Z Z-A

  • A visual history of HIV survival in the UK

    A history of HIV survival in the UK Subscription

    Treatment for HIV has radically improved since the beginning of the epidemic in 1981. HIV-infected people in the UK are now surviving for decades, rather than months or years.

  • Societal attitudes towards HIV need to keep up with the advances in drug development and treatment for the illness. In the illustration, a man is huddled in a corner with a big, red AIDS symbol - ribbon - painted on a wall

    Stigma towards people with HIV will undo advances in drug treatment Subscription

    Societal attitudes towards HIV need to keep up with the advances in drug development and treatment for the illness.

  • Reyataz boosted regimen Subscription

    Ordinarily, treatment of HIV-1 with Reyataz (atazanavir; Bristol Myers Squibb) is boosted by co-administration with ritonavir. However, the summary of product characteristics has been updated to reflect that, under certain circumstances, ritonavir does not need to be co-administered, for example in patients with hepatic impairment. 

  • Sustiva oral solution discontinued Subscription

    Sustiva oral solution 30mg/ml (efavirenz), used to treat HIV infection, has been discontinued by Bristol Myers Squibb. The “capsule sprinkle” method has been upgraded to the primary dosing method for patients who cannot swallow pills. In addition, as a result of the Sustiva oral solution discontinuation, the paediatric indication for the Sustiva hard capsules and film coated tablets has been extended to include children from three months of age and weighing at least 3.5kg.

  • The recent 5000% price increase for toxoplasmosis treatment Daraprim has sparked a wider discussion on the problems in the pharmaceutical industry in the US. In the image, dollar bills inside prescription pill bottles

    Drug price hikes in the United States must be stopped Subscription

    The recent 5,000% price increase for toxoplasmosis treatment Daraprim has sparked a wider discussion on problems with the pharmaceutical industry in the United States.

  • Daklinza for HIV co-infected patients Subscription

    The summary of product characteristics of Daklinza (daclatasvir; Bristol-Myers Squibb) has been updated to reflect the results of a study, which found the medicine is effective at treating hepatitis C when patients are also infected with HIV. This includes changes to the posology and information on interactions with other medicines. 

  • Pharmaceutical Care Awards 2015 audience choice winners Video

    The audience choice winners explain why their Pharmaceutical Care Awards project should be replicated.

  • ‘The chimp and the river’, by David Quammen

    Discovering the origins of HIV Subscription

    ‘The chimp and the river’, by David Quammen.

  • People reluctant to get tested for HIV clinic new home test without professional support

    HIV self testing should not replace face-to-face diagnosis

    People who are reluctant to get tested for HIV at a clinic may opt to use a new home test, but they will do so without professional support.

  • There is growing evidence that pre-exposure prophylaxis is efficacious, safe and cost-effective in preventing high-risk individuals from getting HIV

    Time to expand use of PrEP to prevent spread of HIV infection Subscription

    There is growing evidence that pre-exposure prophylaxis is efficacious, safe and cost-effective in preventing high-risk individuals from getting HIV.

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.